Drug profile

The FDA adverse-event record for Mannheimia Haemolytica Toxoid

26 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mannheimia Haemolytica Toxoid. Species, reactions, and outcomes follow.

#1558 of 2,679
by report volume (all drugs)
26
adverse-event reports
92.3%
death-coded share
Cattle
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Mannheimia Haemolytica Toxoid ranks #1543 of 2679 by total reports (26). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1543
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Mannheimia Haemolytica Toxoid has 26 reports now versus 25 in that prior snapshot: 1 more (4.0%).

Report change
+1
Death-coded reports
+1
Death-coded share
+0.3 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Mannheimia Haemolytica Toxoid changes

Signature read: Mannheimia Haemolytica Toxoid's 92.3% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
26
Total Reports
24
Deaths Reported
92.3%
Death-coded share of reports

Active Ingredients

Mannheimia Haemolytica Toxoid

Administration Routes

UnknownSubcutaneousParenteralIntramuscular

Species Affected

Cattle 26

Most Affected Breeds

Cattle (other) 14
Cattle (unknown) 6
Crossbred Bovine/Cattle 3
Unknown 1
Charolais 1
Aberdeen Angus 1

Most Reported Reactions

Death 21
Lack of efficacy - NOS 9
Respiratory signs 3
Lack of efficacy (virus) - NOS 3
Foaming at the mouth 2
Death by euthanasia 2
INEFFECTIVE, ANTIBIOTIC 2
Anaphylaxis 2
Lack of efficacy (bacteria) - NOS 2
Lack of efficacy (virus) - bovine viral diarrhoea virus 2
Injection site oedema 1
Stiff gait 1

Outcome Breakdown

Died
23 (60.5%)
Outcome Unknown
8 (21.1%)
Recovered/Normal
3 (7.9%)
Euthanized
2 (5.3%)
Ongoing
2 (5.3%)

Mannheimia Haemolytica Toxoid: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Mannheimia Haemolytica Toxoid (#1558 of 2,679 by report volume); death-coded 92.3%. PlainBreed drug row · death-coded share stamp 92.3% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →